Mette Klitgaard

Ms. Mette Klitgaard

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
RBRagna Berthelsen
Ragna Berthelsen
MKMette Klitgaard
Mette Klitgaard
TRThomas Rades
Thomas Rades
AMAnette Mullertz
Anette Mullertz

1 February 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
MFMargherita Falavigna
Margherita Falavigna
MKMette Klitgaard
Mette Klitgaard
CBChristina Brase
Christina Brase
STSelenia Ternullo
Selenia Ternullo
Natasa Skalko-BasnetNatasa Skalko-Basnet
Natasa Skalko-Basnet
GFGoril Eide Flaten
Goril Eide Flaten
The mucus layer covering all mucosal surfaces in our body is the first barrier encountered by drugs before their potential absorption through epithelial tissues, and could thus affect the drugs' permeability and their effectiveness. Therefore, it is of key importance to have in vitro permeability models that can mimic this specific environment. For this purpose, the novel mucus phospholipid vesicle-based permeation assay (mucus-PVPA) has been developed and used for permeability screening of drugs and formulations. The model proved to be stable under the chosen conditions and demonstrated the ability to discriminate between compounds with different chemical structures and properties. Overall, a decrease in drug permeability was found in the presence of mucus on top of the PVPA barriers, as expected. Moreover, mucoadhesive (chitosan-coated) and mucopenetrating (PEGylated) liposomes were investigated in the newly developed model. The mucus-PVPA was able to distinguish between the different liposomal formulations, confirming the penetration potential of the tested formulations and the related drug permeability. The mucus-PVPA model appears to be a promising in vitro tool able to mimic the environment of mucosal tissues, and could therefore be used for further drug permeability screening and formulation development.

30 August 2016 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
PSP. J. Sassene
P. J. Sassene
MMM. H. Michaelsen
M. H. Michaelsen
MMM. D. Mosgaard
M. D. Mosgaard
MKMette Klitgaard
Mette Klitgaard
EBE. Van Den Broek
E. Van Den Broek
AMAnette Mullertz
Anette Mullertz

2 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MKMette Klitgaard
Mette Klitgaard
AMAnette Mullertz
Anette Mullertz
RBRagna Berthelsen
Ragna Berthelsen
The aim of this study was to design an in vitro lipolysis-permeation method to estimate drug absorption following the oral administration of self-nanoemulsifying drug delivery systems (SNEDDSs). The method was evaluated by testing five oral formulations containing cinnarizine (four SNEDDSs and one aqueous suspension) from a previously published pharmacokinetic study in rats. In that study, the pharmacokinetic profiles of the five formulations did not correlate with the drug solubilization profiles obtained during in vitro intestinal lipolysis. Using the designed lipolysis-permeation method, in vitro lipolysis of the five formulations was followed by in vitro drug permeation in Franz diffusion cells equipped with PermeaPad® barriers. A linear in vivo–in vitro correlation was obtained when comparing the area under the in vitro drug permeation–time curve (AUC0–3h), to the AUC0–3h of the plasma concentration–time profile obtained from the in vivo study. Based on these results, the evaluated lipolysis-permeation method was found to be a promising tool for estimating the in vivo performance of SNEDDSs, but more studies are needed to evaluate the method further.

1 April 2019 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
MFMargherita Falavigna
Margherita Falavigna
MKMette Klitgaard
Mette Klitgaard
ESErik Steene
Erik Steene
GFGoril Eide Flaten
Goril Eide Flaten
Intestinal drug absorption following oral administration can be influenced by regional conditions (absorbing surface area, bacterial flora, motility, pH, mucus thickness) and food intake, all of which affect drug solubility and permeability. Therefore, it is crucial to assess the impact of these conditions on the drugability of drugs and formulations. In this study, the ability of the liposome-based mucus-PVPA in vitro permeability model to handle relevant intestinal pH conditions was evaluated, together with the investigation on the pH-dependent solubility and permeability profiles of five model drugs. This study additionally evaluated the impact of all commercially available versions of the fasted and fed state simulated intestinal fluids (SIFs) on the integrity of the barriers, and the permeabilities of one hydrophilic and one lipophilic compound were examined under these conditions. The model was found to be well-functioning in all tested pH conditions, and a pH-dependent trend was found for both solubility and permeability profiles for acidic and basic compounds, according to their degree of ionization. Moreover, the mucus layer and its pH-dependent viscosity particularly influenced the permeation of more lipophilic compounds. The PVPA barriers primarily maintained their functionality in the presence of the fed state SIFs, and the permeability of the two tested compounds showed to be influenced by their hydrophilicity/lipophilicity, their degree of interaction with mucus and by the bile salts and phospholipids content in the SIFs. Overall, the obtained results highlight the relevance of studying the effect that pH, mucus and SIFs have on intestinal drug absorption, and suggest the suitability of the mucus-PVPA model for such investigations.

1 November 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MKMette Klitgaard
Mette Klitgaard
PSPhilip Jonas Sassene
Philip Jonas Sassene
ASArzu Selen
Arzu Selen
AMAnette Mullertz
Anette Mullertz
RBRagna Berthelsen
Ragna Berthelsen